Literature DB >> 11743585

Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection.

Janice M Kelly1, Phillip K Darcy, Jessica L Markby, Dale I Godfrey, Kazuyoshi Takeda, Hideo Yagita, Mark J Smyth.   

Abstract

Natural killer (NK) cells may modulate the development of adaptive immune responses, but until now there has been little evidence to support this hypothesis. We investigated the primary and secondary immunity elicited by various tumor cell lines that express CD70 and interact with CD70 ligand (CD27), which is constitutively expressed on NK cells. CD70 expression enhanced primary tumor rejection in vivo as well as T cell immunity against secondary tumor challenge. Primary rejection of major histocompatibility complex (MHC) class I-deficient RMA-S.CD70 tumor cells was mediated by NK cells and perforin- and interferon-gamma-dependent mechanisms. This NK cell-mediated process also efficiently evoked the subsequent development of tumor-specific cytotoxic and T helper type 1 responses to the parental, MHC class I-sufficient, RMA tumor cells. Thus CD27-CD70 interactions provide a key link between innate NK cell responses and adaptive T cell immunity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11743585     DOI: 10.1038/ni746

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  84 in total

Review 1.  A sense of tumour for the immune system.

Authors:  Stephen Todryk
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

Review 2.  Modulation of host innate and adaptive immune defenses by cytomegalovirus: timing is everything.

Authors:  A Loewendorf; C A Benedict
Journal:  J Intern Med       Date:  2010-05       Impact factor: 8.989

3.  Recipient lymphocyte infusion in MHC-matched bone marrow chimeras induces a limited lymphohematopoietic host-versus-graft reactivity but a significant antileukemic effect mediated by CD8+ T cells and natural killer cells.

Authors:  Lien De Somer; Ben Sprangers; Sabine Fevery; Omer Rutgeerts; Caroline Lenaerts; Louis Boon; Mark Waer; An D Billiau
Journal:  Haematologica       Date:  2010-11-25       Impact factor: 9.941

Review 4.  Boosting vaccine efficacy the natural (killer) way.

Authors:  Carolyn E Rydyznski; Stephen N Waggoner
Journal:  Trends Immunol       Date:  2015-08-10       Impact factor: 16.687

5.  Suppression of natural killer cell-mediated bone marrow cell rejection by CD4+CD25+ regulatory T cells.

Authors:  Isabel Barao; Alan M Hanash; William Hallett; Lisbeth A Welniak; Kai Sun; Doug Redelman; Bruce R Blazar; Robert B Levy; William J Murphy
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-27       Impact factor: 11.205

6.  NK-cell-mediated killing of target cells triggers robust antigen-specific T-cell-mediated and humoral responses.

Authors:  Philippe Krebs; Michael J Barnes; Kristin Lampe; Karen Whitley; Keith S Bahjat; Bruce Beutler; Edith Janssen; Kasper Hoebe
Journal:  Blood       Date:  2009-04-30       Impact factor: 22.113

7.  Combination therapy using IL-2 and anti-CD25 results in augmented natural killer cell-mediated antitumor responses.

Authors:  William H D Hallett; Erik Ames; Maite Álvarez; Isabel Barao; Patricia A Taylor; Bruce R Blazar; William J Murphy
Journal:  Biol Blood Marrow Transplant       Date:  2008-10       Impact factor: 5.742

Review 8.  Stimulating CD27 to quantitatively and qualitatively shape adaptive immunity to cancer.

Authors:  Timothy Nj Bullock
Journal:  Curr Opin Immunol       Date:  2017-03-17       Impact factor: 7.486

9.  Shaping of NK cell responses by the tumor microenvironment.

Authors:  Ana Stojanovic; Margareta P Correia; Adelheid Cerwenka
Journal:  Cancer Microenviron       Date:  2012-12-16

10.  NK cells interfere with the generation of resistance against mycoplasma respiratory infection following nasal-pulmonary immunization.

Authors:  Sheetal Bodhankar; Mathew D Woolard; Xiangle Sun; Jerry W Simecka
Journal:  J Immunol       Date:  2009-07-22       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.